Report Overview

The Brazil Obesity drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

A global obesity epidemic is opening up avenues of growth for the drug industry in developing nations like Brazil, where almost four in 10 adults fall into that category. More than 700 million people are now considered obese worldwide, raising the risk of diabetes, heart disease, and cancer, and driving healthcare costs higher.



Market Drivers

The rapidly increasing population suffering from obesity has led to rising concerns regarding its effective management. The growing awareness among patients, about the timely management of weight gain is anticipated to increase the demand for anti-obesity drugs.

The increasing adoption of unhealthy lifestyle and unhealthy diet plans along with the lack of exercise and consumption of alcohol has led to the growing bodyweight viz., body fat. Moreover, the increasing prevalence of obesity-related disorders, such as diabetes and cardiovascular diseases, has raised concerns regarding the consequences of excess body weight. This is driving the pharmaceutical companies to invest in R&D for the anti-obesity drug launch. A strong drug pipeline is expected to provide lucrative growth opportunities in the forecast period.